From Discovery to the Clinic: Adjuvants and HIV Vaccine Development

The HIV vaccine field has entered a new phase of discovery which includes several adjuvant approaches in preclinical development that are poised to be tested in clinical trials. Selecting and evaluating adjuvants to enhance innate and adaptive immune responses to protein-, DNA- and vector-based HIV-1 vaccine approaches are key challenges that require YECI engagement and input. Through this workshop, hosted by the Global HIV Vaccine Enterprise and the OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation), participants were able to:

  • Review licensed vaccine adjuvants
  • Explore potential mechanisms of action for several licensed adjuvants and those under study, including engagement of innate immune responses (e.g, toll-like receptor agonists)
  • Understand pre-clinical and clinical development pathways for vaccine adjuvants, paying particular attention to regulatory and manufacturing considerations


Workshop participants and faculty



This workshop is supported by the NIH Office of AIDS Research and the Global HIV Vaccine Enterprise. The Capacity-Building Series is a program of the Global HIV Vaccine Enterprise, a unique alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account